Hyperparathyroidism - Drug Pipeline Landscape, 2023
Description
Hyperparathyroidism - Drug Pipeline Landscape, 2023
Hyperparathyroidism is a disease characterized by excessive secretion of parathyroid hormone, an 84-amino acid polypeptide hormone. The secretion of parathyroid hormone is regulated directly by the plasma concentration of ionized calcium. Primary hyperparathyroidism is a common endocrine disorder caused by overactivation of parathyroid glands resulting in excessive release of parathyroid hormone.
Secondary hyperparathyroidism mainly occurs when the calcium proportion in the body is dropped or reduced due to certain core ailments. Prolonged kidney illness also results in lowering Vitamin D and calcium, which results in secondary hyperparathyroidism.
The most common cause of hyperparathyroidism is having a long history of calcium and vitamin deficiencies, chronic kidney failure that results in low vitamin D and calcium levels.
Symptoms of hyperparathyroidism includes exhaustion, weakness of muscle and joints, body pains, loss of appetite, constipated bowels, motion sickness, fatigue, unable to concentrate and confusion, depression, nausea and vomiting, kidney stones etc.
Doctors most often diagnose hyperparathyroidism by general medical examination of the skin, eye, throat, pulse rate. A blood test is performed to detect the calcium level and hormone level of thyroid-stimulating Hormone including T3 and T4. CT, MRI, and Ultrasound Scans are conducted to detect the presence of a tumour or the swelling of the gland.
The most common investigative treatments include are few antithyroid and radioactive iodine medication is taken to control the overproduction of parathyroid hormone. In extreme cases, surgery is performed to remove the thyroid gland. Symptoms can be eased through lifestyle changes and home remedies like Regular walk and exercise for stronger and healthy bones., Intake of more water and fresh fruit juice to avoid dehydration., Having a balanced diet including Vitamin D-rich food and calcium supplements.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Hyperparathyroidism treatment such as Doxercalciferol, Etelcalcetide, CTAP101 and others. Key players involved in the development of therapies to treat Hyperparathyroidism are Amgen, Novadiol Inc, OPKO Health Inc, Sanofi, TaiRx Inc and others. Two drugs are under late-stage Phase III clinical trials and one drug is in Phase II clinical trials and some other drugs are under Phase I and preclinical stages of development.
Report Highlights
Global Insight Service's, Hyperparathyroidism - Drug Pipeline Landscape, 2023 report provides an overview of the Hyperparathyroidism pipeline drugs. This report covers detailed insights on Hyperparathyroidism drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Hyperparathyroidism pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Hyperparathyroidism is a disease characterized by excessive secretion of parathyroid hormone, an 84-amino acid polypeptide hormone. The secretion of parathyroid hormone is regulated directly by the plasma concentration of ionized calcium. Primary hyperparathyroidism is a common endocrine disorder caused by overactivation of parathyroid glands resulting in excessive release of parathyroid hormone.
Secondary hyperparathyroidism mainly occurs when the calcium proportion in the body is dropped or reduced due to certain core ailments. Prolonged kidney illness also results in lowering Vitamin D and calcium, which results in secondary hyperparathyroidism.
The most common cause of hyperparathyroidism is having a long history of calcium and vitamin deficiencies, chronic kidney failure that results in low vitamin D and calcium levels.
Symptoms of hyperparathyroidism includes exhaustion, weakness of muscle and joints, body pains, loss of appetite, constipated bowels, motion sickness, fatigue, unable to concentrate and confusion, depression, nausea and vomiting, kidney stones etc.
Doctors most often diagnose hyperparathyroidism by general medical examination of the skin, eye, throat, pulse rate. A blood test is performed to detect the calcium level and hormone level of thyroid-stimulating Hormone including T3 and T4. CT, MRI, and Ultrasound Scans are conducted to detect the presence of a tumour or the swelling of the gland.
The most common investigative treatments include are few antithyroid and radioactive iodine medication is taken to control the overproduction of parathyroid hormone. In extreme cases, surgery is performed to remove the thyroid gland. Symptoms can be eased through lifestyle changes and home remedies like Regular walk and exercise for stronger and healthy bones., Intake of more water and fresh fruit juice to avoid dehydration., Having a balanced diet including Vitamin D-rich food and calcium supplements.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Hyperparathyroidism treatment such as Doxercalciferol, Etelcalcetide, CTAP101 and others. Key players involved in the development of therapies to treat Hyperparathyroidism are Amgen, Novadiol Inc, OPKO Health Inc, Sanofi, TaiRx Inc and others. Two drugs are under late-stage Phase III clinical trials and one drug is in Phase II clinical trials and some other drugs are under Phase I and preclinical stages of development.
Report Highlights
Global Insight Service's, Hyperparathyroidism - Drug Pipeline Landscape, 2023 report provides an overview of the Hyperparathyroidism pipeline drugs. This report covers detailed insights on Hyperparathyroidism drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Hyperparathyroidism pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
72 Pages
- 1. Introduction
- 1.1 Hyperparathyroidism - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Hyperparathyroidism
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Hyperparathyroidism - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs - Phase III
- 5.5.1 Doxercalciferol
- 5.5.2 Etelcalcetide
- 5.2 Clinical Stage Drugs - Phase II
- 5.2.1 CTAP101
- 5.3 Early Stage Drugs - Preclinical
- 5.3.1 MT1013
- 5.3.2 SHR6508
- 5.3.3 TRX-711
- 5.4 Unknown Stage Drugs
- 5.4.1 Dendrocin
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Amgen
- 9.2 Novadiol Inc
- 9.3 OPKO Health, Inc
- 9.4 Sanofi
- 9.5 Shaanxi Micot Technology Co Ltd
- 9.6 Shanghai Hengrui Pharmaceutical Co Ltd
- 9.7 TaiRx Inc
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1.1 Number of Products under Development by Hyperparathyroidism
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1. 7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - Doxercalciferol/Sanofi
- Table 2.2 Clinical Trial Details - Etelcalcetide/Amgen
- Table 2.3 Clinical Trial Details - CTAP101/OPKO Health Inc
- Table 2.4 Clinical Trial Details - MT1013 /Shaanxi Micot Technology Co Ltd
- Table 2.5 Clinical Trial Details - SHR6508/Shanghai Hengrui Pharmaceutical Co Ltd
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- Table 4.2 Discontinued Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Hyperparathyroidism, 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Hyperparathyroidism, 2023
- Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Hyperparathyroidism, 2023
- Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Hyperparathyroidism, 2023
- Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Hyperparathyroidism, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
